HCP
MYGN icon

Hexagon Capital Partners’s Myriad Genetics MYGN Stock Holding History

Hexagon Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-157
Closed -$1.39K – 1106
2025
Q1 		$1.39K Buy
157
+19
+14% +$228 ﹤0.01% 1485
2024
Q4 		$1.89K Sell
138
-1,074
-89% -$19.8K ﹤0.01% 1431
2024
Q3 		$33.2K Buy
1,212
+69
+6% +$1.87K 0.01% 541
2024
Q2 		$28K Buy
1,143
+491
+75% +$10.8K 0.01% 574
2024
Q1 		$13.9K Buy
652
+277
+74% +$5.96K ﹤0.01% 766
2023
Q4 		$7.18K Buy
+375
New +$6.49K ﹤0.01% 898

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Hexagon Capital Partners's MYGN Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 157 shares — an estimated $1.39K sold.

Hexagon Capital Partners first reported a position in MYGN in Q4 2023 and held it in 6 quarters. The position peaked at $33.2K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 157 Myriad Genetics shares in Q2 2025, an estimated $1.39K.
  • Hexagon Capital Partners first reported a position in Myriad Genetics in Q4 2023 and held it in 6 quarters.
  • Hexagon Capital Partners's Myriad Genetics position peaked at $33.2K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.